Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Inflammatory Response Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Renin Angiotensin Aldosterone System In Septic Kids

NCT06295393
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury Due to Sepsis, Acute Kidney Injury (Nontraumatic)
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
1 Day to 18 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

NCT03736421
View directory record Official record
Conditions
Infection, Hypervolemia, Hypovolemia, Septic Shock, Acute Heart Failure, Congestive Heart Failure
Interventions
Peripheral Intravenous Analysis (PIVA), Non-invasive fluid response measure, Passive leg raise (PLR)
Procedure · Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

NCT04195347
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
CM4620
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
Charlotte, North Carolina • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational

Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

NCT00980915
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction

NCT03893175
View directory record Official record
Conditions
Impacted Third Molar Tooth, Pain, Acute
Interventions
Ibuprofen, Acetaminophen, Placebo, Oxycodone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Phase 4 Interventional

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

NCT07556107
View directory record Official record
Conditions
Infection, Acute Kidney Injury, Sepsis
Interventions
Piperacillin + Tazobactam, meropenem
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Cooperstown, New York • Winston-Salem, North Carolina • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Active, not recruiting Not applicable Interventional

CT for Personalized Mechanical Ventilation

NCT05977153
View directory record Official record
Conditions
Ventilator-Induced Lung Injury, Sepsis Syndrome, Mechanical Ventilation Complication
Interventions
PEEP (positive end-expiratory pressure) - maximum, PEEP (positive end-expiratory pressure) - standard
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555
View directory record Official record
Conditions
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Interventions
Siltuximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Physiologic State Intelligence Study

NCT07814118
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions
OMNIPHYS Multimodal Ultrasound Imaging System
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2046
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

NCT02168946
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational

A Study to Monitor Patients With Primary or Early HIV Infection

NCT00000911
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Sep 22, 2026, 10:05 PM EDT
Completed No phase listed Observational

Lung Injury Prediction Study

NCT00889772
View directory record Official record
Conditions
Respiratory Distress, Acute Lung Injury
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction

NCT01936896
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Alpha 1-Antitrypsin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 4 Interventional

Adrenal Insufficiency in Septic Shock

NCT00842933
View directory record Official record
Conditions
Septic Shock, Acute Adrenal Insufficiency
Interventions
Corticosteroid
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Sep 22, 2026, 10:05 PM EDT
Withdrawn No phase listed Observational

Collective Accuryn Physiologic Signals and Signatures

NCT03817281
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome
Interventions
Accuryn Monitoring System
Device
Lead sponsor
Potrero Medical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 22, 2026, 10:05 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.

NCT06665542
View directory record Official record
Conditions
Sepsis, Acute Infection
Interventions
Not listed
Lead sponsor
MeMed Diagnostics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
New York, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

NCT01734694
View directory record Official record
Conditions
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
Interventions
Vancomycin, Ceftaroline, Daptomycin, Linezolid
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 22, 2026, 10:05 PM EDT
Active, not recruiting No phase listed Observational

Integrating Data, Algorithms and Clinical Reasoning for Surgical Risk Assessment

NCT02741986
View directory record Official record
Conditions
Postoperative Complications
Interventions
Risk estimation
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Phase 1 Interventional

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

NCT07084129
View directory record Official record
Conditions
Sepsis
Interventions
personalized dosing adjustment of vancomycin
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

NCT07215702
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury
Interventions
AZD4144, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Newport Beach, California • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

NCT04537299
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 22, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NCT02384395
View directory record Official record
Conditions
HIV, Acute HIV Infection
Interventions
Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 22, 2026, 10:05 PM EDT